Alex Panas

Amar makes an important point about where industrial growth is headed. In this environment, transformative deals are less about incremental scale and more about reshaping portfolios to meet changing customer demand. Strategic M&A, when paired with active portfolio management, can accelerate entry into new end markets, strengthen differentiation, and clarify the long-term investor thesis. The real opportunity emerges when transactions are aligned to customer needs and powered by AI insight, turning acquisitions into platforms for innovation rather than simple portfolio additions. For industrial leaders, the mandate is to think bigger than expansion. Executed with discipline and anchored in a clear commercial strategy, transformative deals can define the next phase of growth.

26

We are initiating coverage of Varda Space Industries for the America2030 Portfolio at IPO CLUB, strategically focused on investments in Space and Dual-Use technology innovation. Investment Thesis: Varda operates at the forefront of in-space manufacturing, a paradigm-shifting sector set to unlock new commercial possibilities and optimize the production of high-value materials that cannot be manufactured on Earth. By leveraging microgravity environments, Varda aims to deliver products with superior properties for pharmaceutical, semiconductor, and advanced materials industries, while also catering to the unique requirements of defense and government stakeholders. Key Drivers: • Emerging Markets: Rapidly growing interest in microgravity-enabled products, with increasing demand from both commercial and defense sectors. • First Mover Advantage: Proprietary return-to-Earth capabilities position Varda as an early leader in the commercialization of in-space manufacturing. • Dual-Use Readiness: Technologies developed are inherently dual-use, appealing to both private sector innovators and government agencies seeking strategic materials and manufacturing capacities. Risks & Considerations: The in-space manufacturing industry is still in its formative stages, with considerable technological, regulatory, and market adoption risks. Successful execution of return missions and long-term contract acquisition will be pivotal for Varda’s growth trajectory. We see Varda as a high-potential addition to our America 2030 Portfolio, reflecting our conviction in Space and Dual-Use technologies as next-generation growth engines. Latest Update: Varda - In June 2025, Varda launched its fourth W-series mission, debuting its fully in-house satellite bus, heat shield, and a solution-based pharmaceutical processing module—all developed at its El Segundo HQ. This flight marked the first commercial missions under its new FAA re-entry vehicle operator license (Part 450), granting re-entry permissions through 2029.  In July 2025, Varda secured $187 million in Series C funding, led by Natural Capital andShrug Capitall with participation fromFounders Fundd, Peter Thiel,Khosla Venturess,Lux Capitall,Caffeinated Capitall, andAlso Capitall—bringing total funding to approximately $329 million. This round will accelerate its flight cadence and build out expanded pharmaceutical labs, including a 10,000 sq ft facility in El Segundo staffed with structural biologists and crystallization scientists. More on the deal 👉 www.ipo.club/deals/varda #InvestmentResearch #IPOClub #America2030 #SpaceTech #InSpaceManufacturing #DualUse #Innovation

8

MedTech and HealthIT drove record deal volume last year thanks to larger-than-average number of high-value transactions. All signs point to an active year for the sector as portfolios mature and exit pipelines build. Read more: https://okt.to/Ol62IX #healthcare #medtech #HealthIT #MergersAndAcquisitons

44

1 Comment

Conversations at #JPM26 point to biopharma dealmaking accelerating in 2026 as innovation remains strong and market stability improves. Precision-led M&A, sustained premiums for differentiated science, and broader use of AI in diligence and deal structuring are shaping the landscape. Sharing a few takeaways from the conference. Glenn Hunzinger, Greg Rotz, James Woods, Meghan Boudreau, Jaymal Patel, Claude Fuhrer, Philip Sclafani

216

Growth that depends on talent is vulnerable. Growth supported by system is durable. Private equity environments demand commercial engines that can be tuned, measured, and scaled through compressed timelines. My colleague John van Berkum outlines how Strategic RevOps strengthens that foundation: https://lnkd.in/e4QDQq7W

1

As AI continues to accelerate semiconductor revenues, a key question may be how companies navigate concentration risk while positioning for the next wave of value creation. This outlook offers important perspective for leaders thinking through strategy, capex, and R&D priorities.

7

I’m pleased to share that T. Rowe Price portfolios participated in Hadrian’s recent financing round as they expand capital to meet accelerating, generational demand for domestic manufacturing capacity. Across aerospace, defense, and critical infrastructure, the need to rebuild industrial capability in the United States is becoming increasingly clear. Hadrian is scaling a manufacturing platform designed for that moment, pairing advanced automation with workforce training to build capacity at speed and scale. We look forward to supporting the team as they continue executing on this opportunity!

195

4 Comments

A successful post-acquisition stand-up takes more than operational execution. It requires strategic alignment across functions to unlock lasting value. In our latest insight, we explore how organizations can navigate the complexities of standing up a new business unit, from Day 1 readiness to long-term integration. #MergersAndAcquisitions #StrategicExecution #ValueCreation #BusinessTransformation

13

2 Comments

J17 is proud to join Cambium’s $100M Series B, supporting their mission to deliver mission-critical advanced materials across the US and its allies. Cambium fuses AI, chemistry, and HPC to design next-gen polymers at breakthrough speed. Their SHD acquisition creates one of the world’s largest qualified production capacities for aerospace prepregs, films, and adhesives. This powers rapid scaling, secure supply chains, and innovations like ApexShield 1000™ for hypersonics and defense. Congratulations to Simon Waddington and the Cambium team. Here’s to a stronger Western industrial base.

10

Medtech firms that resist passing on input costs, yet raise prices, are seeing the strongest margin lift. Bain shares what’s driving the gains. https://bit.ly/42xxOdO

2